CXCR2 and CXCL4 Regulate Survival and Self-renewal of Hematopoietic Stem/progenitor Cells

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2016 May 26

PMID 27222476

Citations 36

Authors

Amy Sinclair

Laura Park

Mansi Shah

Mark Drotar

Simon Calaminus

Lisa E M Hopcroft

Ross Kinstrie

Amelie V Guitart

Karen Dunn

Sheela A Abraham

Owen Sansom

Alison M Michie

Laura Machesky

Kamil R Kranc

Gerard J Graham

Francesca Pellicano

Tessa L Holyoake

Affiliations

Soon will be listed here.

Abstract

The regulation of hematopoietic stem cell (HSC) survival and self-renewal within the bone marrow (BM) niche is not well understood. We therefore investigated global transcriptomic profiling of normal human HSC/hematopoietic progenitor cells [HPCs], revealing that several chemokine ligands (CXCL1-4, CXCL6, CXCL10, CXCL11, and CXCL13) were upregulated in human quiescent CD34(+)Hoescht(-)Pyronin Y(-) and primitive CD34(+)38(-), as compared with proliferating CD34(+)Hoechst(+)Pyronin Y(+) and CD34(+)38(+) stem/progenitor cells. This suggested that chemokines might play an important role in the homeostasis of HSCs. In human CD34(+) hematopoietic cells, knockdown of CXCL4 or pharmacologic inhibition of the chemokine receptor CXCR2, significantly decreased cell viability and colony forming cell (CFC) potential. Studies on Cxcr2(-/-) mice demonstrated enhanced BM and spleen cellularity, with significantly increased numbers of HSCs, hematopoietic progenitor cell-1 (HPC-1), HPC-2, and Lin(-)Sca-1(+)c-Kit(+) subpopulations. Cxcr2(-/-) stem/progenitor cells showed reduced self-renewal capacity as measured in serial transplantation assays. Parallel studies on Cxcl4 demonstrated reduced numbers of CFC in primary and secondary assays following knockdown in murine c-Kit(+) cells, and Cxcl4(-/-) mice showed a decrease in HSC and reduced self-renewal capacity after secondary transplantation. These data demonstrate that the CXCR2 network and CXCL4 play a role in the maintenance of normal HSC/HPC cell fates, including survival and self-renewal.

Citing Articles

Versatile platelets contribute to rejuvenation.

Perry J, Zhao M Life Med. 2025; 3(3):lnae018.

PMID: 39871892 PMC: 11749376. DOI: 10.1093/lifemedi/lnae018.

Effect of bone marrow niche on hematopoietic stem cells.

Niazi V, Ghafouri-Fard S Histochem Cell Biol. 2024; 163(1):19.

PMID: 39714560 DOI: 10.1007/s00418-024-02348-z.

Adverse effects of CXCR2 deficiency in mice reared under non-gnotobiotic conditions.

Garcia M, Morales M, Yang T, Holden J, Bossardet O, Palmer S Sci Rep. 2024; 14(1):26159.

PMID: 39478033 PMC: 11525579. DOI: 10.1038/s41598-024-75532-9.

Genes Selectively Expressed in Rat Organs.

Li D, Wan X, Yun Y, Li Y, Duan W Curr Genomics. 2024; 25(4):261-297.

PMID: 39156728 PMC: 11327808. DOI: 10.2174/0113892029273121240401060228.

Cxcl10 and Cxcr3 regulate self-renewal and differentiation of hematopoietic stem cells.

Liu F, Sun X, Deng S, Wu Y, Liu X, Wu C Stem Cell Res Ther. 2024; 15(1):248.

PMID: 39113086 PMC: 11304843. DOI: 10.1186/s13287-024-03861-7.

References

Dugan M, Maziarz R, Bensinger W, Nademanee A, Liesveld J, Badel K . Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant. 2009; 45(1):39-47. DOI: 10.1038/bmt.2009.119. View

Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y . TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010; 463(7281):676-80. DOI: 10.1038/nature08734. View

Nie Y, Han Y, Zou Y . CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med. 2008; 205(4):777-83. PMC: 2292218. DOI: 10.1084/jem.20072513. View

Cacalano G, Lee J, Kikly K, Ryan A, Hultgren B, Wood W . Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science. 1994; 265(5172):682-4. DOI: 10.1126/science.8036519. View

Jantunen E, Kuittinen T, Mahlamaki E, Pyorala M, Mantymaa P, Nousiainen T . Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol. 2011; 86(4):299-304. DOI: 10.1111/j.1600-0609.2010.01573.x. View

Tzeng Y, Li H, Kang Y, Chen W, Cheng W, Lai D . Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression. Blood. 2010; 117(2):429-39. DOI: 10.1182/blood-2010-01-266833. View

Broxmeyer H . Chemokines in hematopoiesis. Curr Opin Hematol. 2007; 15(1):49-58. DOI: 10.1097/MOH.0b013e3282f29012. View

Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T . Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999; 283(5403):845-8. DOI: 10.1126/science.283.5403.845. View

Keating G . Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs. 2011; 71(12):1623-47. DOI: 10.2165/11206040-000000000-00000. View

10.

Wilson A, Laurenti E, Oser G, van der Wath R, Blanco-Bose W, Jaworski M . Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008; 135(6):1118-29. DOI: 10.1016/j.cell.2008.10.048. View

11.

Nesmelova I, Sham Y, Gao J, Mayo K . CXC and CC chemokines form mixed heterodimers: association free energies from molecular dynamics simulations and experimental correlations. J Biol Chem. 2008; 283(35):24155-66. PMC: 2527121. DOI: 10.1074/jbc.M803308200. View

12.

Greenbaum A, Hsu Y, Day R, Schuettpelz L, Christopher M, Borgerding J . CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature. 2013; 495(7440):227-30. PMC: 3600148. DOI: 10.1038/nature11926. View

13.

Essers M, Offner S, Blanco-Bose W, Waibler Z, Kalinke U, Duchosal M . IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009; 458(7240):904-8. DOI: 10.1038/nature07815. View

14.

Catusse J, Liotard A, Loillier B, Pruneau D, Paquet J . Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen alpha (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2. Biochem Pharmacol. 2003; 65(5):813-21. DOI: 10.1016/s0006-2952(02)01619-2. View

15.

Zhang B, Ho Y, Huang Q, Maeda T, Lin A, Lee S . Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012; 21(4):577-92. PMC: 3332001. DOI: 10.1016/j.ccr.2012.02.018. View

16.

Bruns I, Lucas D, Pinho S, Ahmed J, Lambert M, Kunisaki Y . Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat Med. 2014; 20(11):1315-20. PMC: 4258871. DOI: 10.1038/nm.3707. View

17.

Broxmeyer H, Cooper S, Cacalano G, Hague N, Bailish E, Moore M . Involvement of Interleukin (IL) 8 receptor in negative regulation of myeloid progenitor cells in vivo: evidence from mice lacking the murine IL-8 receptor homologue. J Exp Med. 1996; 184(5):1825-32. PMC: 2192871. DOI: 10.1084/jem.184.5.1825. View

18.

Pellicano F, Copland M, Jorgensen H, Mountford J, Leber B, Holyoake T . BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta. Blood. 2009; 114(19):4186-96. DOI: 10.1182/blood-2009-05-219550. View

19.

Graham G, Wright E, Hewick R, Wolpe S, Wilkie N, Donaldson D . Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature. 1990; 344(6265):442-4. DOI: 10.1038/344442a0. View

20.

Lu S, Feng Y, Yang R, Liu Y, Zhai Q, Zhang Z . [Effect of platelet factor 4 on the adherence of cord blood CD34(+) cells]. Zhonghua Xue Ye Xue Za Zhi. 2003; 24(9):467-9. View